ISPOR - PCN37 Cost-Effectiveness Analysis of Pembrolizumab Versus Nivolumab As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer in France

PCN37 Cost-Effectiveness Analysis of Pembrolizumab Versus Nivolumab As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer in France

Abstract

Authors

J. Verma D. Verma A. Maria

Full Text Cite This Article

Back to Volume 22, Supplemental S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now